On Mar. 27, 2021, the FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has returned after, at least four prior lines (different types) of therapy.

Abecma, developed by Celgene Corporation, a Bristol Myers Squibb company, is the first cell-based gene therapy approved by the FDA for the treatment of multiple myeloma.